Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, as well as active pharmaceutical ingredients. The company operates with… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amphastar Pharmaceuticals, Inc. does
In the company’s own words
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, as well as active pharmaceutical ingredients. The company operates with a vertically integrated infrastructure that enables it to advance products from research and development through commercialization while maintaining internal control over manufacturing quality and supply chain management.
The company's portfolio includes over 25 marketed prescription pharmaceutical products and one over-the-counter product, Primatene MIST. Major revenue-generating products include BAQSIMI, a nasally administered glucagon for severe hypoglycemia acquired in June 2023; Primatene MIST, an over-the-counter epinephrine inhalation product; and generic injectable products including glucagon, epinephrine, and lidocaine. Recent FDA approvals include albuterol sulfate inhalation aerosol, iron sucrose injection, teriparatide injection, and ipratropium bromide HFA inhalation aerosol. The company generated net revenues of $719.9 million for the fiscal year ended December 31, 2025.
Amphastar operates manufacturing facilities across six locations in the United States, France, and China, comprising approximately 2.5 million square feet of space dedicated to manufacturing, research and development, distribution, and laboratory operations. The company employs 163 dedicated research and development personnel with expertise in pharmaceutical formulation, process development, analytical chemistry, and drug delivery systems.
The company's pipeline includes over 10 product candidates in various development stages, encompassing generic ANDAs, biosimilar candidates with emphasis on interchangeable insulin analogs, and proprietary product candidates targeting oncology, ophthalmology, and other therapeutic areas. Amphastar has established relationships with major pharmaceutical distributors including McKesson, Cencora, and Cardinal Health, which collectively represent approximately 65 percent of net revenues. The company's competitive advantages include advanced technical capabilities in complex molecule characterization, immunogenicity studies, particle engineering, and sustained-release technology, combined with its vertically integrated manufacturing infrastructure and experienced management team with deep scientific expertise.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- RANCHO CUCAMONGA, CA
- Fiscal year end
- December
- CIK
- 1297184
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amphastar Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Amphastar Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amphastar Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Amphastar Pharmaceuticals, Inc.’s debt, $30.27M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.00%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amphastar Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amphastar Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amphastar Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”